for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Grifols SA

GRLS.MC

Latest Trade

25.09EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

21.41

 - 

34.31

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
25.09
Open
--
Volume
--
3M AVG Volume
20.23
Today's High
--
Today's Low
--
52 Week High
34.31
52 Week Low
21.41
Shares Out (MIL)
684.14
Market Cap (MIL)
14,733.23
Forward P/E
--
Dividend (Yield %)
1.44

Next Event

Dividend For GRLSbn.MC - 0.0101 EUR

Latest Developments

More

Grifols Expects Full Recovery Of Its Plasma Volumes By 2021

Grifols Gets Agreement To Buy Remaining Shares Of Alkahest, about 55%, for $146 Mln

Grifols H1 Net Profit Down 23.9% YoY

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Grifols SA

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma for therapeutic use. The Hospital division offers non-biological pharmaceutical products and medical supplies for hospital pharmacy. The Diagnostic division provides clinical analysis and laboratory testing tools to laboratories, hospitals and blood banks. The Raw materials division includes sales of intermediate biological products, as well as manufacturing services to third parties. The Company operates production facilities in Spain, the United States, Mexico and Australia, among others. It controls numerous subsidiaries, such as Kiro Grifols SL.

Industry

Biotechnology & Drugs

Contact Info

C/ Jesus y Maria, 6

BARCELONA, BAR

08022

Spain

+34.935.710000

http://www.grifols.com/es/web/international/home

Executive Leadership

Victor Grifols Roura

Non-Executive Chairman of the Board

Victor Grifols Deu

Co-Chief Executive Officer, Executive Director

Raimon Grifols Roura

Co-Chief Executive Officer, Executive Director

Thomas Glanzmann

Non-Executive Vice Chairman of the Board

Alfredo Arroyo Guerra

Chief Financial Officer

Key Stats

2.24 mean rating - 21 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

4.3K

2018

4.5K

2019

5.1K

2020(E)

5.4K
EPS (EUR)

2017

0.860

2018

0.990

2019

1.050

2020(E)

1.017
Price To Earnings (TTM)
30.97
Price To Sales (TTM)
2.75
Price To Book (MRQ)
3.20
Price To Cash Flow (TTM)
17.82
Total Debt To Equity (MRQ)
126.03
LT Debt To Equity (MRQ)
120.17
Return on Investment (TTM)
5.08
Return on Equity (TTM)
4.26

Latest News

Latest News

Spanish pharma Grifols buys plasma assets from Green Cross for $460 million

Spanish pharmaceutical company Grifols said on Monday it agreed to buy plasma assets in North America from South Korea's Green Cross for $460 million.

BRIEF-Rigel Announces Availability Of Tavlesse® In Europe

* RIGEL ANNOUNCES AVAILABILITY OF TAVLESSE® (FOSTAMATINIB DISODIUM HEXAHYDRATE) IN EUROPE

BRIEF-Grifols To Produce Hyperimmune Immunoglobulin, Potential Passive Immune Therapy Against Covid-19

* STARTS PRODUCTION OF ITS HYPERIMMUNE IMMUNOGLOBULIN AS A POTENTIAL PASSIVE IMMUNE THERAPY AGAINST COVID-19 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Grifols Collaborates With Hologic To Increase Spain's COVID-19 Testing Capacity

* ANNOUNCES COLLABORATION WITH HOLOGIC INC TO INCREASE THE COUNTRY’S TESTING CAPACITY FOR COVID-19

Grifols CFO expects drop in plasma donations to be short-lived

Spanish pharmaceuticals company Grifols expects to recover quickly from a drop in plasma donations that forced it to book a 200 million euro ($226 million) hit in its first-quarter earnings, its chief financial officer said on Monday.

BRIEF-Grifols Says Estimated COVID-19 Impact In 2020 At 200 Mln Euros

* SAYS HAS ESTIMATED A TOTAL IMPACT OF 200 MILLION EUROS FOR THE FISCAL YEAR 2020

BRIEF-Grifols Signs Upsize Of Its Multicurrency Revolving Credit Facility From $500 Mln To $1 Bln

* SAYS HAS SIGNED WITH BANKS THAT WERE PART OF ITS DEBT REFINANCING IN NOV 2019 AN UPSIZE OF ITS MULTICURRENCY REVOLVING CREDIT FACILITY FROM $500 MILLION TO $1 BILLION

BRIEF-Grifols Completes Development Of High Sensitivity Molecular Test To Detect Sars-Cov-2 Virus

* COMPLETES DEVELOPMENT OF VERY HIGH SENSITIVITY MOLECULAR TEST TO DETECT SARS-COV-2 VIRUS

Grifols says anti-coronavirus hyperimmune immunoglobins may be ready mid-July

Spanish pharmaceutical company Grifols said on Tuesday the hyperimmune immunoglobins it is developing as a treatment against SARS-COV-2 could be ready in mid-July.

Grifols says anti-coronavirus hyperimmune immunoglobins may be ready mid-July

Spanish pharmaceutical company Grifols said on Tuesday the hyperimmune immunoglobins it is developing as a treatment against SARS-COV-2 could be ready in mid-July.

BRIEF-Grifols Plasma Centers, Industrial And commercial Sites Open Amid Global Health Crisis

* AMID CURRENT GLOBAL HEALTH CRISIS CAUSED BY COVID-19, GRIFOLS’ PLASMA CENTERS, INDUSTRIAL AND COMMERCIAL SITES REMAIN OPERATIONAL

BRIEF-Grifols Q1 Adjusted Net Profit Up 8% YoY

* Q1 ADJUSTED NET PROFIT 153.1 MILLION EUROS VERSUS 141.8 MILLION EUROS YEAR AGO

BRIEF-Grifols: Requirements For Transaction With Shanghai Raas Blood Products Have Been Consummated

* SAYS ALL LEGAL REQUIREMENTS REQUESTED BY CHINA AND U.S. FOR CLOSING OF TRANSACTION BETWEEN SHANGHAI RAAS BLOOD PRODUCTS CO. LTD. AND GRIFOLS HAVE BEEN CONSUMMATED

BRIEF-Grifols Announces Formal Collaboration With US Government To Produce Treatment Specifically Targeting COVID-19

* SAID ON WEDNESDAY IT HAS ENTERED INTO A FORMAL COLLABORATION WITH THE UNITED STATES BIOMEDICAL ADVANCED RESEARCH DEVELOPMENT AUTHORITY (BARDA), THE FOOD AND DRUG ADMINISTRATION (FDA) AND OTHER FEDERAL PUBLIC HEALTH AGENCIES TO COLLECT PLASMA FROM CONVALESCENT COVID-19...

Spain's Grifols to test plasma therapy for COVID-19 with U.S. FDA

Spain's Grifols has agreed to work with the U.S. Food and Drug Administration and other agencies to gather plasma from patients who have recovered from COVID-19 and test potential therapies for the disease, the pharmaceutical firm said on Wednesday.

BRIEF-Grifols Says Is Able To Provide Uninterrupted Supply Of Its Products

* SAYS ALL EFFORTS ACROSS SUPPLY CHAIN ALLOW THE COMPANY TO PROVIDE UNINTERRUPTED SUPPLY OF ITS PRODUCTS WITH, AT LEAST, HALF A YEAR WORTH INVENTORY ON HAND OF PLASMA AND ITS KEY PROTEINS GLOBALLY

UPDATE 1-Spain's Grifols shares slide after disappointing Q4

Shares in Spanish pharmaceutical company Grifols slipped on Thursday after its fourth-quarter margins disappointed analysts even though annual net profit rose 4.8%.

Spain's Grifols posts 5% profit rise in 2019 on plasma medicines

Spanish pharmaceutical company Grifols posted on Thursday a 4.8% rise in 2019 net profit to 625 million euros ($679 million), mainly due to growth in its blood plasma-derived medicines business.

BRIEF-Grifols FY Net Profit Up 4.8% YoY

* FY NET PROFIT 625.1 MILLION EUROS VERSUS 596.6 MILLION EUROS YEAR AGO

BRIEF-Grifols FY 2019 Net Debt Ratio Decreases To 4.17x

* CONFIRMS ITS COMMITMENT TO REDUCE THE NET DEBT RATIO, WHICH DECREASES TO 4.17X

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up